NCT00445679 - Paroxetine-referenced Study Evaluating Three Doses of DVS SR in Outpatients With MDD | Biotech Hunter

Enrollment

807

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

February 28, 2009

Study Completion Date

February 28, 2009

Conditions

Depressive Disorder, Major

Interventions

DRUG

DVS SR

Arm 1: 50mg DVS SR tablet, QD, 8 weeks treatment with 2 week taper Arm 2: 100mg DVS SR tablet, QD, 8 weeks treatment with 2 week taper Arm 3: 200mg DVS SR tablet, QD, 8 weeks treatment with 2 week taper

DRUG

Paroxetine

20 mg Paroxetine capsule, QD, 8 weeks treatment with 2 week taper

Trial Locations (43)

100083

Beijing

100088

Beijing

110002

New Delhi

141001

Punjab

160012

Chandigarh

200030

Shanghai

200065

Shanghai

210029

Jiangsu Province

226003

Uttar Pradesh

310003

Zhejiang Province

380006

Gujarat

380013

Gujarat

410011

Hunan Province

411001

Maharashtra

500034

Andhra Pradesh

510370

Guangdong Province

575018

Karnataka

610041

Sichuan Province

650032

Yunnan Province

710032

Shanxi Province

500 038

Andhra Pradesh

517 507

Andhra Pradesh

530 002

Andhra Pradesh

575 001

Karnataka

400 012

Maharashtra

400 026

Maharashtra

H19400 022

Mumbai Maharashtra

400-711

Incheon

110-744

Seoul

135-710

Seoul

135-720

Seoul

137-701

Seoul

138-736

Seoul

140-757

Seoul

150-719

Seoul

158-710

Seoul

ROC 500

Chang-hua

ROC 80708

Kaohsiung City

ROC 100

Taipei

ROC 111

Taipei

ROC 112

Taipei

ROC 114

Taipei

ROC 220

Taipei

All Listed Sponsors

lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY